0001199835-20-000216.txt : 20200814 0001199835-20-000216.hdr.sgml : 20200814 20200814170527 ACCESSION NUMBER: 0001199835-20-000216 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200814 DATE AS OF CHANGE: 20200814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENETHERA INC CENTRAL INDEX KEY: 0001017110 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650622463 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27237 FILM NUMBER: 201106433 BUSINESS ADDRESS: STREET 1: 3051 W 105TH AVENUE STREET 2: UNIT 350251 CITY: WESTMINSTER STATE: CO ZIP: 80031 BUSINESS PHONE: 3035069367 MAIL ADDRESS: STREET 1: 3051 W 105TH AVENUE STREET 2: UNIT 350251 CITY: WESTMINSTER STATE: CO ZIP: 80031 FORMER COMPANY: FORMER CONFORMED NAME: HAND BRAND DISTRIBUTION INC DATE OF NAME CHANGE: 19990818 10-Q 1 form-10q.htm GENETHERA, INC. 10-Q
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended June 30, 2020

 

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM ______ TO _________

 

Commission File Number:

000-27237

 

(GENETHERA LOGO)

 

GeneThera, Inc.

(Exact name of registrant as Specified in its Charter)

 

Nevada 65-0622463
(State or Other Jurisdiction of (Internal Revenue Service
Incorporation or Organization) Employer Identification Number)

 

3051 W. 105th Ave. #350251, Westminster, CO 80035
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code:  

(720) 587-5100

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

None

 

Securities registered pursuant to Section 12(g) of the Exchange Act:

Common Stock, $0.001 per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-Q or any amendment to this Form 10-Q. Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, and accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o Accelerated filer o
Non-accelerated filer o

Smaller reporting company x

Emerging growth company o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes o No x

 

State the number of shares of the issuer’s common stock outstanding, as of the latest practicable date: 35,902,602 shares of common stock issued and outstanding as of August 14, 2020. 

1

 

PART I – FINANCIAL INFORMATION

 

FORWARD-LOOKING AND CAUTIONARY STATEMENTS

 

Sections of this Form 10-Q, including Business and Management’s Discussion and Analysis or Plan of Operation, contain “forward-looking statements”. These forward-looking statements are subject to risks and uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. You should not unduly rely on these statements. Forward-looking statements involve assumptions and describe our plans, strategies, and expectations. You can generally identify a forward-looking statement by words such as may, will, should, would, could, plan, goal, potential, expect, anticipate, estimate, believe, intend, project, and similar words and variations thereof. This report contains forward-looking statements that address, among other things:

 

* Our financing plans,
   
* Regulatory environments in which we operate or plan to operate, and
   
* Trends affecting our financial condition or results of operations, the impact of competition, the start-up of certain operations and acquisition opportunities.

 

Factors, risks, and uncertainties that could cause actual results to differ materially from those in the forward-looking statements (“Cautionary Statements”) include, among others:

 

* Our ability to raise capital,
   
* Our ability to execute our business strategy in a very competitive environment,
   
* Our degree of financial leverage, risks associated with our acquiring and integrating companies into our own,
   
* Risks relating to rapidly developing technology, and regulatory considerations,
   
* Risks related to international economies,
   
* Risks related to market acceptance and demand for our products and services,
   
* The impact of competitive services and pricing, and
   
* Other risks referenced from time to time in our SEC filings.

 

All subsequent written and oral forward-looking statements attributable to us, or anyone acting on our behalf, are expressly qualified in their entirety by the cautionary statements. We do not undertake any obligations to publicly release any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect unanticipated events that may occur.

2

 

Item 1. Financial Statements.

 

GeneThera, Inc.

 

June 30, 2020

 

Index to the Condensed Consolidated Financial Statements

 

Condensed Consolidated Balance Sheets as of June 30, 2020 (Unaudited) and December 31, 2019 4
   
Condensed Consolidated Statements of Operations for the Three and Six Months ended June 30, 2020 and 2019 (unaudited) 5
   
Condensed Consolidated Statements of Changes in Stockholder’s Deficit for the Three and Six Months Ended June 30, 2020 and 2019 (unaudited) 6
   
Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2020 and 2019 (unaudited) 7
   
Notes to the Condensed Consolidated Financial Statements (unaudited) 8

3

 

GeneThera, Inc.

 

Condensed Consolidated Balance Sheets

 

   June 30,
2020
     
   (unaudited)   December 31, 2019 
ASSETS          
Current assets          
Cash  $-   $5,309 
Prepaid expenses   922    - 
Total current assets   922    5,309 
Property and equipment          
Automobile & Trucks   26,400    26,400 
Less: Accumulated depreciation   (13,200)   (10,560)
Total property and equipment, net   13,200    15,840 
Other assets   -    - 
TOTAL ASSETS  $14,122   $21,149 
           
LIABILITIES & STOCKHOLDERS’ DEFICIT          
Current liabilities          
Accounts payable  $28,748   $27,705 
Accrued expenses   6,432,802    6,092,364 
Notes payable   25,800    25,800 
Convertible notes payable, net of discount   54,500    54,500 
Loan from shareholder   735,330    741,778 
Total liabilities   7,277,180    6,942,147 
           
Commitments and Contingencies   -    - 
           
Stockholders’ deficit:          
Series A preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively   -    - 
Series B preferred stock, par value $0.001 per share, 30,000,000 shares authorized, 26,038,572 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively   26,039    26,039 
Common stock, par value $0.001 per share, 300,000,000 shares authorized, 35,902,602 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively   35,904    35,904 
Common stock to be issued   53,572    53,572 
Additional paid-in capital   23,448,986    23,448,986 
Accumulated deficit   (30,824,559)   (30,485,499)
Total stockholders’ deficit of GeneThera, Inc.   (7,260,058)   (6,920,998)
TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT  $14,122   $21,149 

 

See accompanying notes to unaudited condensed consolidated financial statements.

4

 

GeneThera, Inc.

 

Condensed Consolidated Statements of Operations

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30 
   2020   2019   2020   2019 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
Expenses                    
General and administrative expenses  $76,241   $19,676   $100,128   $60,085 
Payroll expenses   116,500    116,500    233,000    233,000 
Research and Development   -    -    -    - 
Depreciation   1,320    1,320    2,640    2,640 
Total operating expenses   194,061    137,496    335,768    295,725 
Loss from operations   (194,061)   (137,496)   (335,768)   (295,725)
Other expenses                    
Interest expense   (1,646)   (9,512)   (3,292)   (19,024)
    -    -    -    - 
Total other expense   (1,646)   (9,512)   (3,292)   (19,024)
Other Income                    
    -    -    -    - 
Total other Income   -    -    -    - 
Net loss before income taxes   (195,707)   (147,008)   (339,060)   (314,749)
Provision for income taxes   -    -    -    - 
Net loss  $(195,707)  $(147,008)  $(339,060)  $(314,749)
Loss per common share - Basic and diluted  $(0.01)  $(0.00)  $(0.01)  $(0.01)
Weighted average common shares outstanding - Basic and diluted   35,902,602    35,902,602    35,902,602    35,902,602 

 

See accompanying notes to unaudited condensed consolidated financial statements.

5

 

GeneThera, Inc.

 

Condensed Consolidated Statements of Stockholders’ (Deficit)
(Unaudited)

 

For the Three Months Ended June 30, 2020

 

   Series A   Series B       Additional             
   Preferred Stock   Preferred Stock   Common Stock   Paid-In   Accumulated   Stock to be     
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Issued   Total 
Balance at March 31, 2020   -   $-    26,038,572   $26,039    35,902,602   $35,904   $23,448,986   $(30,628,852)  $53,572   $(7,064,351)
                                                   
Net Loss   -    -    -    -    -    -    -    (195,707)   -    (195,707)
Balance at June 30, 2020   -   $-    26,038,572   $26,039    35,902,602   $35,904   $23,448,986   $(30,824,559)  $53,572   $(7,260,058)

 

For the Three Months Ended June 30, 2019

 

   Series A   Series B       Additional             
   Preferred Stock   Preferred Stock   Common Stock   Paid-In   Accumulated   Stock to be     
   Shares   Amount   Shares   Amount   Shares   Shares   Capital   Deficit   Issued   Total 
Balance at March 31, 2019   10,350   $12    26,038,572   $26,039    35,902,602   $35,904   $22,568,815   $(30,135,591)  $53,572   $(7,451,248)
                                                   
Net Loss   -    -    -    -    -    -    -    (147,008)   -    (147,008)
Balance at June 30, 2019   10,350   $12    26,038,572   $26,039    35,902,602   $35,904   $22,568,815   $(30,282,599)  $53,572   $(7,598,256)

 

For the Six Months Ended June 30, 2020

 

   Series A   Series B       Additional             
   Preferred Stock   Preferred Stock   Common Stock   Paid-In   Accumulated   Stock to be     
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Issued   Total 
Balance at December 31, 2019   -   $-    26,038,572   $26,039    35,902,602   $35,904   $23,448,986   $(30,485,499)  $53,572   $(6,920,998)
                                                   
Net Loss   -    -    -    -    -    -    -    (339,060)   -    (339,060)
Balance at June 30, 2020   -   $-    26,038,572   $26,039    35,902,602   $35,904   $23,448,986   $(30,824,559)  $53,572   $(7,260,058)

 

For the Six Months Ended June 30, 2019

 

   Series A   Series B       Additional             
   Preferred Stock   Preferred Stock   Common Stock   Paid-In   Accumulated   Stock to be     
   Shares   Amount   Shares   Amount   Shares   Shares   Capital   Deficit   Issued   Total 
Balance at December 31, 2018   10,350   $12    26,038,572   $26,039    35,902,602   $35,904   $22,568,815   $(29,967,850)  $53,572   $(7,283,507)
                                                   
Net Loss   -    -    -    -    -    -    -    (314,749)   -    (314,749)
Balance at June 30, 2019   10,350   $12    26,038,572   $26,039    35,902,602   $35,904   $22,568,815   $(30,282,599)  $53,572   $(7,598,256)

 

See accompanying notes to the unaudited condensed consolidated financial statements.

6

 

GeneThera, Inc.

 

Condensed Consolidated Statements of Cash Flows

 

   For the Six Months Ended 
   June 30, 
   2020
(unaudited)
   2019
(unaudited)
 
Cash flows from operating activities          
Net loss  $(339,060)  $(314,749)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation   -    - 
Depreciation and amortization   2,640    2,640 
Shares issued for services   -    - 
Changes in operating assets and liabilities:          
Prepaid Expenses   (922)   (852)
Deposits   (3,000)   12,000 
Accounts receivable - related parties   -    - 
Accounts payable and accrued expenses - related parties   (6,448)   - 
Accounts payable and accrued expenses   341,481    295,921 
Net cash used in operating activities   (5,309)   (5,040)
           
Cash flows from investing activities          
Purchase of Fixed Asset   -    - 
Net cash used in investing activities   -    - 
Cash flows from financing activities          
Proceeds from convertible notes   -    - 
Net cash provided by financing activities   -    - 
           
Net decrease in cash   (5,309)   (5,040)
Cash at the beginning of the year   5,309    5,040 
Cash at the end of the year  $-   $- 

 

See accompanying notes to unaudited condensed consolidated financial statements.

7

 

GENETHERA, INC.
June 30, 2020

Notes to the Condensed Consolidated Financial Statements
(Unaudited)

 

Note 1 – Organization and nature of operations and summary of significant accounting policies

 

Organization and nature of operations

 

The consolidated financial statements include GeneThera, Inc. and its wholly owned subsidiary GeneThera, Inc. (Colorado) (collectively, the “Company”). The Company had a long-standing research collaboration with GTI Research.

 

The Company is a biotechnology company that develops molecular assays and therapeutics for the detection and treatment for COVID-19 and other zoonotic diseases.

 

Basis of Presentation – Unaudited Financial Information

 

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2019 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC.

 

Use of estimates

 

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation.

 

Principles of consolidation

 

The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany accounts are eliminated upon consolidation.

 

Cash and cash equivalents

 

Cash equivalents are highly liquid investments with an original maturity of three months or less.

 

Fair Value of Financial Instruments

 

For purpose of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. The carrying amount of the Company’s short-term financial instruments approximates fair value due to the relatively short period to maturity for these instruments.

 

Property and equipment, net

 

Property and equipment consist primarily of office and laboratory equipment, leasehold improvements, vehicle, and is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives ranging from five to seven years. Leasehold improvements are amortized over the shorter of their economic lives or lease terms.

8

 

Fair Value of Financial Instruments

 

The Company follows ASC 820-10 of the FASB Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial instruments. ASC 820-10 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820-10 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by ASC 820-10 are described below:

 

Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
   
Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
   
Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data.
   

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

 

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.

 

Transactions involving related parties typically cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist.

 

Reclassifications

 

Certain prior period amounts have been reclassified to conform to current period presentation.

 

Impairment of Long-Lived Assets

 

The Company reviews the recoverability of its long-lived assets to determine whether events or changes in circumstances occurred that indicate the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the asset from the expected future cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying value. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.

 

Revenue recognition

 

There were no revenues during the six months ended June 30, 2020 and 2019, respectively.

 

The Company follows the FASB Accounting Standards Codification ASC 606 – Revenues from Contracts with Customers for revenue recognition. The Company considers revenue realized or realizable and earned when all the following criteria are met:

 

1)Identification of the contract with a customer;

 

2)Identification of the performance obligations in the contract;

 

3)Determination of the transaction price;

 

4)Allocation of the transaction price to the performance obligations in the contract; and

 

5)Recognition of revenue when or as a performance obligation is satisfied. Revenue is recognized when each performance obligation is satisfied by the entity. An estimate of the variable consideration or performance obligations that an entity ultimately expects to be entitled to is included in the transaction price, and revenue is recognized upon satisfaction of the related performance obligation(s). An implicit or explicit significant financing component is taken into consideration. IP licenses must be analyzed. Each contract with customers is analyzed for multiple elements if any element must stand alone.

9

 

Leases

 

The lease agreement was terminated in April 2019. No right of use asset and liability were recorded for this lease.

 

On January 1, 2019, the Company adopted ASC 842 using the modified retrospective approach and will recognize a right of use (“ROU”) asset and liability in the consolidated balance sheet when and if the Company enters into a qualifying lease agreement.

 

At contract inception, the Company determines whether an arrangement is or contains a lease and whether the lease should be classified as an operating or a financing lease. A contract is or contains a lease if the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Control is determined based on the right to obtain all of the economic benefits from use of the identified asset and the right to direct the use of the identified asset. ROU assets for operating leases represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments.

 

Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement, as well as any variable rate payments that depend on an index, initially measured using the index at the lease commencement date. Non-lease components are accounted for separately from the fixed lease component for all leases. Most of the Company’s leases do not provide an implicit rate that can readily be determined. Therefore, the applied discount rate is based on the Company’s incremental borrowing rate, which is determined using its credit rating and other information available as of the commencement date and is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Lease terms may include options to renew, which the Company factors into the determination of the lease term when it is reasonably certain that the Company will exercise that option. The ROU asset is measured at the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.

 

Operating lease expense is recognized on a straight-line basis over the lease term and is included in “Cost of sales” and “Selling, general and administrative” line items in the Company’s consolidated statements of comprehensive income. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases is recognized on a straight-line basis over the lease term.

 

The Company monitors for events or changes in circumstances that require a reassessment of its leases. When a reassessment results in the premeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the ROU asset unless doing so would reduce the ROU asset to an amount less than zero, in which case the remaining adjustment would be recorded in the consolidated statements of comprehensive income.

 

Stock-Based Compensation

 

Stock-based compensation is accounted for under FASB ASC Topic No. 718 – Compensation – Stock Compensation. The guidance requires recognition in the financial statements of the cost of employee services received in exchange for an award of equity instruments over the period the employee is required to perform the services in exchange for the award (presumptively the vesting period). The guidance also requires measurement of the cost of employee services received in exchange for an award based on the grant-date fair value of the award. The Company accounts for non-employee share-based awards in accordance with guidance related to equity instruments that are issued to other than employees for acquisition, or in conjunction with selling, goods or services.

 

Research and development costs

 

R&D cost are currently expensed as incurred and primarily include cost associated with R&D arrangements with external parties in connection with the Company’s robotic technology project.

 

Income taxes

 

Income taxes are accounted for in accordance with the provisions of FASB ASC Topic No. 740 - Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized.

10

 

Basic and diluted net loss per common share

 

Basic and diluted net loss per share calculations are presented in accordance with FASB ASC Topic No. 260 – Earnings per Share and are calculated on the basis of the weighted average number of common shares outstanding during the period. Diluted per share calculations includes the dilutive effect of common stock equivalents in years with net income. As the Company is in a loss position, any calculation of the dilutive effects of the Company’s convertible securities would reduce the loss per share amount, and, as such, the Company will not perform the calculation.

 

Shipping and Handling Costs

 

The Company accounts for shipping and handling fees in accordance with paragraph 605-45-45-19 of the FASB Accounting Standards Codification. While amounts charged to customers for shipping products are included in revenues, the related costs are classified in cost of revenue as incurred.

 

Shipping and handling costs were $0 and $0 for the six months ended June 30, 2020 and 2019, respectively

 

Recently issued accounting pronouncements

 

 In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 provides optional expedients and exceptions to account for contracts, hedging relationships and other transactions that reference LIBOR or another reference rate if certain criteria are met. The amendments of ASU No. 2020-04 are effective immediately, as of March 12, 2020, and may be applied prospectively to contract modifications made and hedging relationships entered into on or before December 31, 2022. The Company is evaluating the impact that the amendments of this standard would have on the Company’s consolidated financial statements

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes(Topic 740): “Simplifying the Accounting for Income Taxes”, which is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending existing guidance to improve consistent application. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. Certain amendments within this ASU are required to be applied on a retrospective basis, certain other amendments are required to be applied on a modified retrospective basis and all other amendments on a prospective basis. The Company is currently evaluating the impact the adoption of this standard will have on the consolidated financial statements.

 

Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company.

 

Note 2- Going Concern

 

As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $30,824,559 and negative working capital of $7,276,258 as of June 30, 2020. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

 

Presently, the Company is considering ways to apply its molecular robotic technology to address the COVID-19 pandemic. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

 

Note 3 – Property and Equipment

 

As of June 30, 2020, the Company had a vehicle with a net book value of $13,200.

11

 

Note 4 – Related party transactions

 

The Company has an outstanding loan payable and accrued interest to Antonio Milici, its CEO and stockholder amounting to $679,783 as of June 30, 2020 and December 31, 2019, respectively. This outstanding loan to the Company is unsecured and bears interest at 2.41%. The Company has an outstanding loan and accrued interest payable to Tannya Irizarry, its interim CFO interim and stockholder, amounting to $55,547 and $61,995 as of June 30, 2020 and December 31, 2019, respectively. This outstanding loan to the Company is unsecured and bears interest at 8%.

 

Tannya Irizarry owns 50% of GTI Corporate Transfer Agents, LLC, and the Company’s transfer agency. During the six months ended June 30, 2020 and 2019, the Company made payments to GTI Corporate Transfer Agents, LLC in the amounts of $22,946 and $4,500, respectively.

 

The Company will no longer rely on GTI Research, Inc. (“GTIR”), the Company’s previous scientific robotic technology collaborator, for conducting research and development activities on the robotic technology development project. The lease agreement with GTI Research, Inc. was terminated on April 29, 2019. We have other collaborators which will be announced at a later time.

 

The Company utilizes Elia Holdings, LLC for construction and other maintenance services to maintain the Company’s office and lab space. Elia Holdings, LLC is controlled by Rene Irizarry. Costs incurred related to such services were $11,225 and $0 during the six-month periods ended June 30, 2020 and 2019, respectively.

 

Note 5 – Accrued expenses

 

The Company’s accrued expenses consisted of the following:

 

   June 30, 2020   December 31, 2019 
Accrued officer salaries (see below)  $5,105,900   $4,872,900 
Accrued interest   196,187    192,895 
Other   1,130,716    1,026,569 
   $6,432,803   $6,092,781 

 

Note 6 – Convertible notes payable

 

The Company’s issued convertible notes are due on demand, bearing interest at an annual rate of 8%. The notes are convertible into shares of Company common stock at a conversion price of $0.01 to $0.05 per share. As of June 30, 2020 and December 31, 2019, the total outstanding principal and interest is $54,500.

 

As of December 31, 2019, an analysis of the principal amount of convertible notes payable that have elected conversion into common stock amounted to $366,000. The Company’s transfer agent has been constrained in its efforts to issue the common stock for these convertible notes due to the noncompliance of the Company’s filing requirements. The Company has ceased accruing interest on these convertible notes but continues to accrue interest on the remaining convertible notes of $54,500. The convertible notes that have elected conversion without the stock being issued have been included in ‘Accrued liabilities’ on the Balance Sheet.

 

Note 7 - Shareholders’ equity

 

Preferred Stock

 

The Company has authorized 20,000,000 shares of Series A Preferred Stock, $.001 par value, and 30,000,000 shares of Series B Preferred Stock, $.001 par value.

 

As of June 30, 2020, and December 31, 2019, the Company had 0 shares Series A Preferred Stock issued and outstanding respectively.

 

As of June 30, 2020, and December 31, 2019, the Company had 26,038,572 shares of Series B Preferred Stock issued and outstanding respectively.

 

Common stock

 

The Company has authorized 300,000,000 shares of its common stock, $.001 par value. The Company had issued and outstanding 35,902,602 shares as of June 30, 2020 and December 31, 2019, respectively.

12

 

Note 8 – Commitments

 

Employment Agreements

 

In 2017, the Company entered into five-year employment agreements with its chief executive and scientific officer and its chief administrative and financial officer. The agreements provide for compensation of $21,500 and $17,333 per month, respectively, and expires on January 31, 2022.

 

The agreements also provide for an aggregate bonus of $135,000 to be paid in Series B Preferred stock in March of each year of the agreement. There are not enough authorized shares to continue issuing the $135,000 worth of Series B Preferred stock, thus, beginning in 2019, the $135,000 was included as in the total payroll accrual.

 

Office Space Lease

 

The Company has a temporary office space at 4685 W 127th Pl, in Broomfield, CO as of June 30, 2020 until new space is completed after renovations. The lease term does not warrant the establishment of a right of use asset or liability. No asset or liability has been recorded on the balance sheet.

  

On April 3, 2020, GeneThera entered into a preliminary agreement with Green RV Storage LLC for the purchase of a 16,000 square foot building located in the planned Northwest 36 Biotechnology Center in Broomfield, Colorado. The new state of the art facility will be the Company administrative and R&D facility. The development is scheduled to be completed in fall of 2021.

 

Note 9 – Subsequent events

 

The impact of COVID-19 on the Company is unknown at this time. The financial consequences of this situation cause uncertainty as to the future and its effects on the economy and the Company.

 

Presently, the Company is considering ways to apply its molecular robotic technology to address the COVID-19 pandemic

 

As of June 30, 2020, no additional conversions of convertible notes have occurred, and no new convertible notes have been issued.

13

 

ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Sections of this Form 10-Q, including the Management’s Discussion and Analysis or Plan of Operation, contain “forward-looking statements”.  These forward-looking statements are subject to risks and uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements.  You should not unduly rely on these statements.  Forward-looking statements involve assumptions and describe our plans, strategies, and expectations.  You can generally identify a forward-looking statement by words such as “may,” “will,” “should,” “would,” “could,” “plans,” “goal,” “potential,” “expect,” “anticipate,” “estimate,” “believe,” “intent,” “project,” and similar words and variations thereof.  This report contains forward-looking statements that address, among other things,

 

*Our financing plans

 

*Regulatory environments in which we operate or plan to operate

 

*Trends affecting our financial condition or results of operations

 

*The impact of competition, the start-up of certain operations and acquisition opportunities.

 

Factors, risks, and uncertainties that could cause actual results to differ materially from those in the forward-looking statements (“Cautionary Statements”) include, among others,

 

*Our ability to raise capital

 

*Our ability to execute our business strategy in a very competitive environment

 

*Our degree of financial leverage

 

*Risks associated with our acquiring and integrating companies into our own

 

*Risks relating to rapidly developing technology

 

*Regulatory considerations

 

*Risks related to international economies

 

*Risks related to market acceptance and demand for our products and services

 

*The impact of competitive services and pricing

 

*Other risks referenced from time to time in our SEC filings

 

All subsequent written and oral forward-looking statements attributable to us, or anyone acting on our behalf, are expressly qualified in their entirety by the cautionary statements.  We do not undertake any obligations to publicly release any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect unanticipated events that may occur.

 

You should read the following discussion of our results and plan of operation in conjunction with the consolidated financial statements and the notes thereto appearing elsewhere in this Form 10-Q.  Statements in this Management’s Discussion and Analysis or Plan of Operation that are not statements of historical or current objective fact are “forward-looking statements.”

 

OVERVIEW

 

We have developed proprietary diagnostic assays for use in the COVID-19 together with agricultural and veterinary markets.  Specific assays for COVID-19; Chronic Wasting Disease (CWD) (among elk and deer) and Mad Cow Disease (among cattle) have been developed and are available currently on a limited basis.  E. coli (predominantly cattle) and Johne’s disease (predominantly cattle and bison) diagnostics are in development.  We are also working on vaccine solutions to meet the growing demands of today’s veterinary industry and tomorrow’s agriculture and healthcare industries.  The Company is organized and operated both to continually apply its scientific research to more effective management of diseases and, in so doing, realize the commercial potential of molecular biotechnology.

14

 

Our business model is based on the development of a proprietary Molecular Robotic/AI Laboratory Platform (“MORAP”), which would combine the use of advanced robotic laboratory systems integrated with AI software systems on a global scale. Upon development, MORAP would encompass a nationwide network of interactive molecular laboratories operated using advanced integrated robotic and machine learning cloud-based software systems, which would be able to share data and interact with each other. We believe MORAP would be capable of processing millions of samples and collecting, storing and analyzing data. We believe that MORAP nationwide communications network could be accomplished through advanced cloud-based software systems, machine learning and Internet-of-Things (IoT) networks. Upon development, MORAP could be readily replicated and scaled utilizing identical instrumentation and software.

 

We have not generated significant operating revenue as of June 30, 2020. Our ability to generate substantial operating revenue will depend on our ability to develop and obtain approval for molecular assays and developing therapeutic vaccines for the detection and prevention of food contaminating pathogens, veterinary diseases, and diseases affecting human health.

 

Our independent auditors have expressed substantial doubt about our ability to continue as a going concern in their report on our consolidated financial statements as of June 30, 2020 and 2019.  For the six months ended June 30, 2020 and 2019, our operating losses were $339,060 and $314,749, respectively.  Our current liabilities exceeded current assets by $7,276,258 and $6,936,838 as of June 30, 2020 and December 31, 2019, respectively.

 

Although, we completed an equity financing with gross proceeds of approximately $1.1 million in 2005, we will require significant additional funding in order to achieve our business plan.  Over the next 12 months, in order to have the capability of achieving our business plan, we believe that we will require at least $40,000,000 in additional funding. We will attempt to raise these funds by both means of one or more private offerings of debt or equity securities.  In such events, we may need immediate additional funding.  Our capital requirements will depend on many factors including, but not limited to, the timing of further development of assays to detect the presence of infectious disease from the blood of live animals, our hiring of additional personnel, the applications for, and receipt of, regulatory approvals for any veterinary vaccines that we may develop, and other factors.  Our ability to raise capital will increase our ability to implement our business plan.

 

We also expect to spend a significant amount of our capital on research and development activities for commercialization relating to development and vaccine design/development.  When we are able to develop assays for different diseases, we intend to formalize the procedure into a commercial application through a series of laboratories to be owned and operated by GeneThera.  To date, we have introduced our diagnostic solution for Chronic Wasting Disease (CWD) and Mad Cow Disease on a very limited basis.  We anticipate that significant funds will be spent on research and development throughout the life of the Company, as this is the source for new products to be introduced to the market.  Our plan is to seek new innovations in the robotic biotechnology field.  We may be successful in developing or validating any new assays and, when we are successful in developing and validating any such assays, we may be able to successfully commercialize them or earn profits from sales of those assays.  Furthermore, we may be able to design, develop, or successfully commercialize vaccines as a result of our research and development efforts.

 

RELATED PARTY TRANSACTIONS

 

The Company has an outstanding loan payable and accrued interest to Antonio Milici, its CEO and stockholder amounting to $679,7783 as of June 30, 2020 and December 31, 2019, respectively. This outstanding loan to the Company is unsecured and bears interest at 2.41%. The Company has an outstanding loan and accrued interest payable to Tannya Irizarry, its CFO interim and stockholder, amounting to $55,547 and $61,995 as of June 30, 2020 and December 31, 2019, respectively. This outstanding loan to the Company is unsecured and bears interest at 8%.

 

GTI Corporate Transfer Agents, LLC is the Company’s transfer agency.  Michelle Torres Colón is the managing director with a 50% ownership and/or interest. Tannya Irizarry is a board member and also has a 50% ownership and/or interest. During the six months ended June 30, 2020, the Company paid GTI Corporate Transfer Agents, LLC $22,946.

 

RECENTLY ISSUED ACCOUNTING STANDARDS

 

Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and find no recent accounting pronouncements that would have a material impact on the financial statements of the Company.

15

 

EMPLOYEES

 

As of March 31, 2020, we had a total of two full-time employees who devoted substantial effort on our behalf. None of our employees are represented by a collective bargaining unit.  We entered into an employment agreement with Antonio Milici, M.D., Ph.D., to serve as our Chief Executive Officer and Chief Scientific Officer through January 31, 2022.  In consideration for his services, Dr. Milici will receive a base salary of $258,000 per annum plus bonuses as may be determined by the Board of Directors at its sole discretion.  As part of his employment agreement, Dr. Milici is subject to non-disclosure and non-competition obligations and has transferred to the Company all of his interests in any idea, concept, technique, invention or written work.  We also entered into an employment agreement with Tannya L. Irizarry to serve as our Chief Administrative Officer through January 31, 2022.  Since May 2006, Ms. Irizarry is also our Chief Financial Officer (Interim). Ms. Irizarry’s base salary is $208,000 per annum.   There are no employee issues at this time.

 

RESULTS OF OPERATIONS

 

FOR THE THREE MONTHS ENDED JUNE 30, 2020 and 2019

 

The company did not generate any revenue for the three months ended June 30, 2020 and 2019.

 

The company had total operating expenses of $194,061 for the three months ended June 30, 2020, compared to total operating expenses of $137,496 for the three months ended June 30, 2019, an increase of $56,565 from the prior period. The increase is due in part to legal and consulting fees, rent and supplies.

 

We had a net loss of $195,707 and $147,008 for the three months ended June 30, 2020 and 2019, respectively, resulting in an increase of $48,699 from the prior period due to increases in legal, consulting, rent and supplies expenses.

 

FOR THE SIX MONTHS ENDED JUNE 30, 2020 and 2019

 

The company did not generate any revenue for the six months ended June 30, 2020 and 2019.

 

The company had total operating expenses of $335,768 for the six months ended June 30, 2020, compared to total operating expenses of $295,725 for the six months ended June 30, 2019, an increase of $40,043 from the prior period. The increase is a result of higher legal and consulting, rent and supplies expenses.

 

We had a net loss of $339,060 and $314,749 for the six months ended June 30, 2020 and 2019, respectively, an increase of $24,311 from the prior period due to increases in legal and consulting, rent and supplies expenses during the current period.

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of June 30, 2020, we had cash and cash equivalents of $0. We have historically financed activities with cash from the private placement of equity and debt securities and advances from related parties. Our auditors have issued a going concern opinion. This means that our auditors believe there is a substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay our bills. We have had negligible revenues since inception and had an accumulated deficit of $30,824,559 and negative working capital of $7,276,258 as of June 30, 2020.

 

Our current cash balance is not sufficient to fund our business objectives and we will need significant additional capital over the next 12-18 months in order to fund our planned operations. Specifically, we intend to spend significant funds on completing our robotic prototype system, validating and testing our products, seeking necessary regulatory approvals and focusing on international expansion. We will attempt to raise capital through one or more private offerings of debt or equity securities or both. We may not be able to secure the financing that we believe is necessary to implement our strategic objectives and, even if additional financing is secured, we may not achieve our strategic objectives. As of the date of this report, we do not have any firm commitments from any investors for any additional funding.

 

Our longer-term working capital and capital requirements will depend upon numerous factors, including revenue and profit generation, pre-clinical studies and clinical trials, the timing and cost of obtaining regulatory approvals, the cost of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights, competing technological and market developments, collaborative arrangements. Additional capital will be required in order to attain such goals. Such additional funds may not become available on acceptable terms and we cannot give assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term.

 

The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of liabilities that may result from the outcome of this uncertainty. If we are unable to obtain additional working capital, our business may fail. Accordingly, we must raise cash from sources other than operations. To date, we have financed our operations primarily through cash flow from limited operations, augmented by cash proceeds from financing activities, short-term borrowings and equity contributions by our stockholders. We must raise cash to implement our projected plan of operations. Failure to obtain capital to fund short-term and long-term needs will likely result in the curtailment of our operations or cessation of certain aspects of our business strategy.

 

The Company has no off-balance sheet commitments or arrangements.

16

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

 

Item 4. Controls and Procedures.

 

(a) Evaluation of Disclosure Controls and Procedures

 

Pursuant to Rule 13a-15(b) under the Exchange Act, the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Principal Executive Officer (“PEO”) and Principal Financial Officer (“PFO”), of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s PEO and PFO concluded that the Company’s disclosure controls and procedures were not effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s PEO and PFO, as appropriate, to allow timely decisions regarding required disclosure

 

(b) Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

The Company is committed to improving financial organization. As part of this commitment, management and the Board perform reviews of the Company’s policies and procedures as they relate to financial reporting in an effort to mitigate future risks of potential misstatements. The Company will continue to focus on developing and documenting internal controls and procedures surrounding the financial reporting process, primarily through the use of account reconciliations, and supervision.

17

 

PART II - OTHER INFORMATION

 

ITEM 1.LEGAL PROCEEDINGS

 

Unless otherwise noted, these judgements are accrued in accounts payable.

 

On November 26, 2012, the Internal Revenue Service filed a Federal Tax Lien in the amount of $1,275. The Company has not satisfied the lien.

 

On November 14, 2014, Litchfield Church Ranch, LLC filed a Summons in Forcible Entry and Detainer against the Company after the owner was unable to sell the building to us because he was upended for over $800,000 in his mortgage. As per the Summons, the plaintiff claimed $364,968.69 in past due rent. As per our accounting records, the Company had $242,000 with the offer to purchase such property at $1,850,000 plus scheduled payments for the past due rent. The owner’s bank did not allow him to sell the property to the Company and/or anyone. We went to mediation. The owner’s legal team and our legal team settled for $115,000 with the contingency to pay the goodwill amount of $15,000 by September 12, 2015. The $15,000 was timely paid. The Company had an additional six months to complete the remaining $100,000 settlement. If not paid off prior to August 12, 2016, there would be no discount and the Company would owe the judgment balance in the amount of $325,885. The mediator, a retired judge, found in our favor. Therefore, the settlement was agreed upon by both parties. The Company did not pay the settlement agreement as of December 31, 2017 and default interest of 18% was accrued on the outstanding judgment balance through December 31, 2018. In July 2019, Litchfield Church Ranch, LLC was dissolved. The Company claims that no money is owed.

 

On January 31, 2019, the Company went to arbitration against FOGT, LLC for breaching their contract agreement. On March 9, 2019, the Company’s legal team, received an emergency relief injunction against FOGT, LLC for $25,000. Fredric Oeschger refused to pay. On April 10, 2019, another emergency relief injunction was granted to our Company. Fredric Oeschger refused to pay. On or before the end of August 2019, the United States Second Circuit Appeals Court, ordered FOGT, LLC and GeneThera, Inc. to have a mandatory mediation. On September 3, 2019, FOGT, LLC and GeneThera Inc. agreed to settle the case against FOGT for breach of contract. On September 6, 2019, FOGT, LLC and GeneThera, Inc. reached a settlement of $425,000. The legal team received $171,000 from this settlement resulting in net proceeds to the Company of approximately $254,000.

 

  Item 1A. Risk Factors

 

There have been no material changes from the risk factors previously disclosed in the Company’s Annual Report on Form 10-K, filed with the Commission on June 10, 2020 and investors are encouraged to review such risk factors prior to making an investment in the Company.

 

  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

As of August 14, 2020, the Company issued no new securities.

 

  Item 3. Defaults upon Senior Securities

 

None.

 

  Item 4: Mine Safety Disclosures

 

Not applicable.

 

  Item 5: Other Information

 

There is no other information required to be disclosed under this item which has not been previously disclosed.

18

 

  Item 6: Exhibits

 

Exhibit
Number
Description of Exhibit
31.1* Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

31.2* Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

32.1* Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

32.2* Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

19

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 14, 2020.

 

GeneThera, Inc.

 

By:   /s/ Antonio Milici
  Antonio Milici, M.D., Ph.D.
  President
  (Principal Executive Officer)

 

By:   /s/ Tannya L. Irizarry
  Tannya L. Irizarry
  Chief Financial Officer (Interim)
  (Principal Financial/Accounting Officer)

 

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
 /s/ Antonio Milici   President, Director   08/14/20
Antonio Milici, M.D., PhD.        
         
 /s/ Tannya L. Irizarry   Chief Financial Officer (Interim)   08/14/20
Tannya L Irizarry        

20

EX-31.1 2 ex31-1.htm CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 

 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Antonio Milici, certify that:

 

1. I have reviewed this Form 10-Q for the fiscal quarter ended June 30, 2020 of GeneThera, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 14, 2020

 

/s/ Antonio Milici  
Antonio Milici
President and Chief Executive Officer

(Principal Executive Officer)

 

 

EX-31.2 3 ex31-2.htm CERTIFICATE OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 

 

EXHIBIT 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Tannya L. Irizarry, certify that:

 

1.I have reviewed this Form 10-Q for the fiscal quarter ended June 30, 2020 of GeneThera, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 14, 2020

 

/s/ Tannya L. Irizarry  
Tannya L. Irizarry  
Chief Financial Officer (Interim)
(Principal Financial/Accounting Officer)

 

EX-32.1 4 ex32-1.htm CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 

 

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Antonio Milici, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of GeneThera, Inc. for the quarterly period ended June 30, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of GeneThera, Inc.

 

By: /s/ Antonio Milici  
Name:  Antonio Milici
Title: President and Chief Executive Officer

(Principal Executive Officer)

 

Date: August 14, 2020

 

EX-32.2 5 ex32-2.htm CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 

 

Exhibit 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Tannya L. Irizarry, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of GeneThera, Inc. for the quarterly period ended June 30, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of GeneThera, Inc.

 

By:  /s/ Tannya L Irizarry  
Name:  Tannya L Irizarry  
Title: Chief Financial Officer (Interim)  

(Principal Financial/Accounting Officer)

 

Date: August 14, 2020

 

GRAPHIC 6 gt001_v1.jpg GRAPHIC begin 644 gt001_v1.jpg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end EX-101.INS 7 gnth-20200630.xml XBRL INSTANCE FILE 0001017110 2020-01-01 2020-06-30 0001017110 2020-08-14 0001017110 2020-06-30 0001017110 2019-12-31 0001017110 us-gaap:SeriesAPreferredStockMember 2020-06-30 0001017110 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001017110 us-gaap:SeriesBPreferredStockMember 2020-06-30 0001017110 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001017110 2019-01-01 2019-06-30 0001017110 srt:ChiefExecutiveOfficerMember 2020-06-30 0001017110 srt:ChiefExecutiveOfficerMember 2019-12-31 0001017110 srt:ChiefOperatingOfficerMember 2020-06-30 0001017110 srt:ChiefOperatingOfficerMember 2019-12-31 0001017110 us-gaap:TransferAgentMember 2020-01-01 2020-06-30 0001017110 us-gaap:TransferAgentMember 2019-01-01 2019-06-30 0001017110 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001017110 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001017110 us-gaap:CommonStockMember 2019-12-31 0001017110 us-gaap:CommonStockMember 2020-06-30 0001017110 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001017110 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001017110 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001017110 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001017110 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001017110 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001017110 us-gaap:RetainedEarningsMember 2019-12-31 0001017110 us-gaap:RetainedEarningsMember 2020-06-30 0001017110 gnth:SharesToBeIssuedMember 2020-01-01 2020-06-30 0001017110 gnth:SharesToBeIssuedMember 2019-01-01 2019-06-30 0001017110 gnth:SharesToBeIssuedMember 2019-12-31 0001017110 gnth:SharesToBeIssuedMember 2020-06-30 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-06-30 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-06-30 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-12-31 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-06-30 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-06-30 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-06-30 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2019-12-31 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-06-30 0001017110 gnth:OfficeAndLaboratoryEquipmentMember srt:MinimumMember 2020-01-01 2020-06-30 0001017110 gnth:OfficeAndLaboratoryEquipmentMember srt:MaximumMember 2020-01-01 2020-06-30 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2018-12-31 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-06-30 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2018-12-31 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2019-06-30 0001017110 us-gaap:CommonStockMember 2018-12-31 0001017110 us-gaap:CommonStockMember 2019-06-30 0001017110 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001017110 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001017110 us-gaap:RetainedEarningsMember 2018-12-31 0001017110 us-gaap:RetainedEarningsMember 2019-06-30 0001017110 gnth:SharesToBeIssuedMember 2018-12-31 0001017110 gnth:SharesToBeIssuedMember 2019-06-30 0001017110 2018-12-31 0001017110 2019-06-30 0001017110 2020-04-01 2020-06-30 0001017110 2019-04-01 2019-06-30 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-03-31 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-03-31 0001017110 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2019-03-31 0001017110 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001017110 us-gaap:CommonStockMember 2020-03-31 0001017110 us-gaap:CommonStockMember 2019-03-31 0001017110 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001017110 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001017110 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001017110 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001017110 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001017110 us-gaap:RetainedEarningsMember 2020-03-31 0001017110 us-gaap:RetainedEarningsMember 2019-03-31 0001017110 gnth:SharesToBeIssuedMember 2020-04-01 2020-06-30 0001017110 gnth:SharesToBeIssuedMember 2019-04-01 2019-06-30 0001017110 gnth:SharesToBeIssuedMember 2020-03-31 0001017110 gnth:SharesToBeIssuedMember 2019-03-31 0001017110 2020-03-31 0001017110 2019-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Genethera Inc 0001017110 10-Q 2020-06-30 false --12-31 Non-accelerated Filer Q2 2020 35902602 false true 14122 21149 -7260058 -6920998 35904 36504 23448986 23448986 -30485499 -30824559 53572 53572 26039 26039 12 12 26039 26039 35904 35904 22568815 22568815 -29967850 -30282599 53572 53572 -7283507 -7598256 12 26039 26039 35904 35904 23448986 22568815 -30628852 -30135591 53572 53572 -7064351 -7451248 -30824559 -30485499 23448986 23448986 35904 35904 26039 26039 7277180 6942147 7277180 6942147 735330 741778 679783 679783 55547 61995 54500 54500 25800 25800 6432802 6092364 28748 27705 14122 21149 13200 15840 13200 10560 26400 26400 922 5309 5309 5040 53572 53572 0.001 0.001 0.001 0.001 20000000 20000000 30000000 30000000 0 0 26038572 26038572 0.001 0.001 300000000 300000000 35902602 35902602 35902602 35902602 0 0 26038572 26038572 -335768 -295725 -194061 -137496 335768 295725 194061 137496 2640 2640 233000 233000 116500 116500 100128 60085 76241 19676 3292 19024 1646 9512 3292 19024 1646 9512 -339060 -314749 -339060 -314749 -195707 -147008 -195707 -147008 -339060 -314749 -195707 -147008 -0.01 -0.01 -0.01 -0.00 35902602 35902602 35902602 35902602 -5309 -5040 -6448 341481 295921 -5309 -5040 7276258 22946 600 5105900 4872900 196187 192895 1130716 1026569 false 000-27237 35902602 35902602 26038572 26038572 10350 10350 26038572 26038572 35902602 35902602 10350 26038572 26038572 35902602 35902602 P5Y P7Y Yes Yes NV true 922 2640 2640 1320 1320 -922 -852 -3000 12000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8211; Organization and nature of operations and summary of significant accounting policies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Organization and nature of operations</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include GeneThera, Inc. and its wholly owned subsidiary GeneThera, Inc. (Colorado) (collectively, the &#8220;Company&#8221;). The Company had a long-standing research collaboration with GTI Research.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a biotechnology company that develops molecular assays and therapeutics for the detection and treatment for COVID-19 and other zoonotic diseases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation &#8211; Unaudited Financial Information</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2019 and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period&#8217;s presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Principles of consolidation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany accounts are eliminated upon consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash and cash equivalents</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash equivalents are highly liquid investments with an original maturity of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purpose of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. The carrying amount of the Company&#8217;s short-term financial instruments approximates fair value due to the relatively short period to maturity for these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Property and equipment, net</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist primarily of office and laboratory equipment, leasehold improvements, vehicle, and is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives ranging from five to seven years. Leasehold improvements are amortized over the shorter of their economic lives or lease terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows ASC 820-10 of the FASB Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial instruments. ASC 820-10 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820-10 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by ASC 820-10 are described below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; width: 7%; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td style="line-height: normal; width: 93%; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of the Company&#8217;s financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Transactions involving related parties typically cannot be presumed to be carried out on an arm&#8217;s-length basis, as the requisite conditions of competitive, free-market dealings may not exist.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been reclassified to conform to current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Impairment of Long-Lived Assets</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews the recoverability of its long-lived assets to determine whether events or changes in circumstances occurred that indicate the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the asset from the expected future cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying value. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenue recognition</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no revenues during the six months ended June 30, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the FASB Accounting Standards Codification ASC 606 &#8211; Revenues from Contracts with Customers for revenue recognition. The Company considers revenue realized or realizable and earned when all the following criteria are met:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">1)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Identification of the contract with a customer&#894;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Identification of the performance obligations in the contract&#894;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">3)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Determination of the transaction price&#894;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">4)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Allocation of the transaction price to the performance obligations in the contract&#894; and</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">5)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Recognition of revenue when or as a performance obligation is satisfied. Revenue is recognized when each performance obligation is satisfied by the entity. An estimate of the variable consideration or performance obligations that an entity ultimately expects to be entitled to is included in the transaction price, and revenue is recognized upon satisfaction of the related performance obligation(s). An implicit or explicit significant financing component is taken into consideration. IP licenses must be analyzed. Each contract with customers is analyzed for multiple elements if any element must stand alone.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Leases</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The lease agreement was terminated in April 2019. No right of use asset and liability were recorded for this lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2019, the Company adopted ASC 842 using the modified retrospective approach and will recognize a right of use (&#8220;ROU&#8221;) asset and liability in the consolidated balance sheet when and if the Company enters into a qualifying lease agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At contract inception, the Company determines whether an arrangement is or contains a lease and whether the lease should be classified as an operating or a financing lease. A contract is or contains a lease if the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Control is determined based on the right to obtain all of the economic benefits from use of the identified asset and the right to direct the use of the identified asset. ROU assets for operating leases represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement, as well as any variable rate payments that depend on an index, initially measured using the index at the lease commencement date. Non-lease components are accounted for separately from the fixed lease component for all leases. Most of the Company&#8217;s leases do not provide an implicit rate that can readily be determined. Therefore, the applied discount rate is based on the Company&#8217;s incremental borrowing rate, which is determined using its credit rating and other information available as of the commencement date and is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Lease terms may include options to renew, which the Company factors into the determination of the lease term when it is reasonably certain that the Company will exercise that option. The ROU asset is measured at the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating lease expense is recognized on a straight-line basis over the lease term and is included in &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative&#8221; line items in the Company&#8217;s consolidated statements of comprehensive income. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases is recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company monitors for events or changes in circumstances that require a reassessment of its leases. When a reassessment results in the premeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the ROU asset unless doing so would reduce the ROU asset to an amount less than zero, in which case the remaining adjustment would be recorded in the consolidated statements of comprehensive income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation is accounted for under FASB ASC Topic No. 718 &#8211; <i>Compensation &#8211; Stock Compensation</i>. The guidance requires recognition in the financial statements of the cost of employee services received in exchange for an award of equity instruments over the period the employee is required to perform the services in exchange for the award (presumptively the vesting period). The guidance also requires measurement of the cost of employee services received in exchange for an award based on the grant-date fair value of the award. The Company accounts for non-employee share-based awards in accordance with guidance related to equity instruments that are issued to other than employees for acquisition, or in conjunction with selling, goods or services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Research and development costs</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">R&#38;D cost are currently expensed as incurred and primarily include cost associated with R&#38;D arrangements with external parties in connection with the Company&#8217;s robotic technology project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Income taxes</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes are accounted for in accordance with the provisions of FASB ASC Topic No. 740 - <i>Income Taxes</i>. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basic and diluted net loss per common share</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic and diluted net loss per share calculations are presented in accordance with FASB ASC Topic No. 260 &#8211; <i>Earnings per Share </i>and are calculated on the basis of the weighted average number of common shares outstanding during the period. Diluted per share calculations includes the dilutive effect of common stock equivalents in years with net income. <font style="color: rgb(34, 34, 34)">As the Company is in a loss position, any calculation of the dilutive effects of the Company&#8217;s convertible securities would reduce the loss per share amount, and, as such, the Company will not perform the calculation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Shipping and Handling Costs</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for shipping and handling fees in accordance with paragraph 605-45-45-19 of the FASB Accounting Standards Codification. While amounts charged to customers for shipping products are included in revenues, the related costs are classified in cost of revenue as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shipping and handling costs were $0 and $0 for the six months ended June 30, 2020 and 2019, respectively</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recently issued accounting pronouncements</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;In March 2020, the FASB issued ASU No. 2020-04, &#8220;<i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>.&#8221; ASU 2020-04 provides optional expedients and exceptions to account for contracts, hedging relationships and other transactions that reference LIBOR or another reference rate if certain criteria are met. The amendments of ASU No. 2020-04 are effective immediately, as of March 12, 2020, and may be applied prospectively to contract modifications made and hedging relationships entered into on or before December 31, 2022. The Company is evaluating the impact that the amendments of this standard would have on the Company&#8217;s consolidated financial statements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12, <i>Income Taxes(Topic 740): &#8220;Simplifying the Accounting for Income Taxes&#8221;</i>, which is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending existing guidance to improve consistent application. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. Certain amendments within this ASU are required to be applied on a retrospective basis, certain other amendments are required to be applied on a modified retrospective basis and all other amendments on a prospective basis. The Company is currently evaluating the impact the adoption of this standard will have on the consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (&#8220;ASU&#8221;) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2- Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $30,824,559 and negative working capital of $7,276,258 as of June 30, 2020. This raises substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Presently, the Company is considering ways to apply its molecular robotic technology to address the COVID-19 pandemic. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 &#8211; Property and Equipment</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2020, the Company had a vehicle with a net book value of $13,200.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8211; Related party transactions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has an outstanding loan payable and accrued interest to Antonio Milici, its CEO and stockholder amounting to $679,783 as of June 30, 2020 and December 31, 2019, respectively. This outstanding loan to the Company is unsecured and bears interest at 2.41%. The Company has an outstanding loan and accrued interest payable to Tannya Irizarry, its interim CFO interim and stockholder, amounting to $55,547 and $61,995 as of June 30, 2020 and December 31, 2019, respectively. This outstanding loan to the Company is unsecured and bears interest at 8%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tannya Irizarry owns 50% of GTI Corporate Transfer Agents, LLC, and the Company&#8217;s transfer agency. During the six months ended June 30, 2020 and 2019, the Company made payments to GTI Corporate Transfer Agents, LLC in the amounts of $22,946 and $4,500, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will no longer rely on GTI Research, Inc. (&#8220;GTIR&#8221;), the Company&#8217;s previous scientific robotic technology collaborator, for conducting research and development activities on the robotic technology development project. The lease agreement with GTI Research, Inc. was terminated on April 29, 2019. We have other collaborators which will be announced at a later time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes Elia Holdings, LLC for construction and other maintenance services to maintain the Company&#8217;s office and lab space. Elia Holdings, LLC is controlled by Rene Irizarry. Costs incurred related to such services were $11,225 and $0 during the six-month periods ended June 30, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>N</b></font><b>ote 5 &#8211; Accrued expenses</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s accrued expenses consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table align="center" cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center; text-indent: -8.65pt; padding-bottom: 1pt; padding-left: 8.65pt; white-space: nowrap">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap">June 30, 2020</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap">December 31, 2019</td> <td style="border-bottom: black 1pt solid">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 66%; text-align: left; text-indent: -8.65pt; padding-bottom: 1pt; padding-left: 8.65pt">Accrued officer salaries (see below)</td> <td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">5,105,900</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td> <td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">4,872,900</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; text-indent: -8.65pt; padding-bottom: 1pt; padding-left: 8.65pt">Accrued interest</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">196,187</td> <td style="text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">192,895</td> <td style="text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-indent: -8.65pt; padding-bottom: 1pt; padding-left: 8.65pt">Other</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,130,716</td> <td style="text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,026,569</td> <td style="text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -8.65pt; padding-bottom: 2.5pt; padding-left: 8.65pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">6,432,803</td> <td style="border-bottom: black 2.5pt double; text-align: left; white-space: nowrap">&#160;</td> <td style="border-bottom: black 2.5pt double">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">6,092,781</td> <td style="border-bottom: black 2.5pt double; text-align: left; white-space: nowrap">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 &#8211; Convertible notes payable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s issued convertible notes are due on demand, bearing interest at an annual rate of 8%. The notes are convertible into shares of Company common stock at a conversion price of $0.01 to $0.05 per share. As of June 30, 2020 and December 31, 2019, the total outstanding principal and interest is $54,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2019, an analysis of the principal amount of convertible notes payable that have elected conversion into common stock amounted to $366,000. The Company&#8217;s transfer agent has been constrained in its efforts to issue the common stock for these convertible notes due to the noncompliance of the Company&#8217;s filing requirements. The Company has ceased accruing interest on these convertible notes but continues to accrue interest on the remaining convertible notes of $54,500. The convertible notes that have elected conversion without the stock being issued have been included in &#8216;Accrued liabilities&#8217; on the Balance Sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7 - Shareholders&#8217; equity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has authorized 20,000,000 shares of Series A Preferred Stock, $.001 par value, and 30,000,000 shares of Series B Preferred Stock, $.001 par value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2020, and December 31, 2019, the Company had 0 shares Series A Preferred Stock issued and outstanding, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2020, and December 31, 2019, the Company had 26,038,572 shares of Series B Preferred Stock issued and outstanding, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has authorized 300,000,000 shares of its common stock, $.001 par value. The Company had issued and outstanding 35,902,602 shares as of June 30, 2020 and December 31, 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 &#8211; Commitments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Employment Agreements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2017, the Company entered into five-year employment agreements with its chief executive and scientific officer and its chief administrative and financial officer. The agreements provide for compensation of $21,500 and $17,333 per month, respectively, and expires on January 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The agreements also provide for an aggregate bonus of $135,000 to be paid in Series B Preferred stock in March of each year of the agreement. There are not enough authorized shares to continue issuing the $135,000 worth of Series B Preferred stock, thus, beginning in 2019, the $135,000 was included as in the total payroll accrual.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Office Space Lease</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has a temporary office space at 4685 W 127<sup>th</sup> Pl, in Broomfield, CO as of June 30, 2020 until new space is completed after renovations. The lease term does not warrant the establishment of a right of use asset or liability. No asset or liability has been recorded on the balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 3, 2020, GeneThera entered into a preliminary agreement with Green RV Storage LLC for the purchase of a 16,000 square foot building located in the planned Northwest 36 Biotechnology Center in Broomfield, Colorado. The new state of the art facility will be the Company administrative and R&#38;D facility. The development is scheduled to be completed in fall of 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9 &#8211; Subsequent events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The impact of COVID-19 on the Company is unknown at this time. The financial consequences of this situation cause uncertainty as to the future and its effects on the economy and the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Presently, the Company is considering ways to apply its molecular robotic technology to address the COVID-19 pandemic</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2020, no additional conversions of convertible notes have occurred, and no new convertible notes have been issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Organization and nature of operations</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include GeneThera, Inc. and its wholly owned subsidiary GeneThera, Inc. (Colorado) (collectively, the &#8220;Company&#8221;). The Company had a long-standing research collaboration with GTI Research.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a biotechnology company that develops molecular assays and therapeutics for the detection and treatment for COVID-19 and other zoonotic diseases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation &#8211; Unaudited Financial Information</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2019 and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period&#8217;s presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Principles of consolidation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany accounts are eliminated upon consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash and cash equivalents</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash equivalents are highly liquid investments with an original maturity of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purpose of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. The carrying amount of the Company&#8217;s short-term financial instruments approximates fair value due to the relatively short period to maturity for these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Property and equipment, net</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist primarily of office and laboratory equipment, leasehold improvements, vehicle, and is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives ranging from five to seven years. Leasehold improvements are amortized over the shorter of their economic lives or lease terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows ASC 820-10 of the FASB Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial instruments. ASC 820-10 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820-10 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by ASC 820-10 are described below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; width: 7%; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td style="line-height: normal; width: 93%; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</font></td></tr> <tr style="line-height: normal; vertical-align: top; font-size-adjust: none; font-stretch: normal"> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="line-height: normal; text-align: justify; font-size-adjust: none; font-stretch: normal"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of the Company&#8217;s financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Transactions involving related parties typically cannot be presumed to be carried out on an arm&#8217;s-length basis, as the requisite conditions of competitive, free-market dealings may not exist.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been reclassified to conform to current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Impairment of Long-Lived Assets</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews the recoverability of its long-lived assets to determine whether events or changes in circumstances occurred that indicate the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the asset from the expected future cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying value. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenue recognition</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no revenues during the six months ended June 30, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the FASB Accounting Standards Codification ASC 606 &#8211; Revenues from Contracts with Customers for revenue recognition. The Company considers revenue realized or realizable and earned when all the following criteria are met:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">1)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Identification of the contract with a customer&#894;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Identification of the performance obligations in the contract&#894;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">3)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Determination of the transaction price&#894;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">4)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Allocation of the transaction price to the performance obligations in the contract&#894; and</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.3in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">5)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Recognition of revenue when or as a performance obligation is satisfied. Revenue is recognized when each performance obligation is satisfied by the entity. An estimate of the variable consideration or performance obligations that an entity ultimately expects to be entitled to is included in the transaction price, and revenue is recognized upon satisfaction of the related performance obligation(s). An implicit or explicit significant financing component is taken into consideration. IP licenses must be analyzed. Each contract with customers is analyzed for multiple elements if any element must stand alone.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Leases</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The lease agreement was terminated in April 2019. No right of use asset and liability were recorded for this lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2019, the Company adopted ASC 842 using the modified retrospective approach and will recognize a right of use (&#8220;ROU&#8221;) asset and liability in the consolidated balance sheet when and if the Company enters into a qualifying lease agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At contract inception, the Company determines whether an arrangement is or contains a lease and whether the lease should be classified as an operating or a financing lease. A contract is or contains a lease if the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Control is determined based on the right to obtain all of the economic benefits from use of the identified asset and the right to direct the use of the identified asset. ROU assets for operating leases represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement, as well as any variable rate payments that depend on an index, initially measured using the index at the lease commencement date. Non-lease components are accounted for separately from the fixed lease component for all leases. Most of the Company&#8217;s leases do not provide an implicit rate that can readily be determined. Therefore, the applied discount rate is based on the Company&#8217;s incremental borrowing rate, which is determined using its credit rating and other information available as of the commencement date and is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Lease terms may include options to renew, which the Company factors into the determination of the lease term when it is reasonably certain that the Company will exercise that option. The ROU asset is measured at the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating lease expense is recognized on a straight-line basis over the lease term and is included in &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative&#8221; line items in the Company&#8217;s consolidated statements of comprehensive income. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases is recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company monitors for events or changes in circumstances that require a reassessment of its leases. When a reassessment results in the premeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the ROU asset unless doing so would reduce the ROU asset to an amount less than zero, in which case the remaining adjustment would be recorded in the consolidated statements of comprehensive income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation is accounted for under FASB ASC Topic No. 718 &#8211; <i>Compensation &#8211; Stock Compensation</i>. The guidance requires recognition in the financial statements of the cost of employee services received in exchange for an award of equity instruments over the period the employee is required to perform the services in exchange for the award (presumptively the vesting period). The guidance also requires measurement of the cost of employee services received in exchange for an award based on the grant-date fair value of the award. The Company accounts for non-employee share-based awards in accordance with guidance related to equity instruments that are issued to other than employees for acquisition, or in conjunction with selling, goods or services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Research and development costs</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">R&#38;D cost are currently expensed as incurred and primarily include cost associated with R&#38;D arrangements with external parties in connection with the Company&#8217;s robotic technology project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Income taxes</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes are accounted for in accordance with the provisions of FASB ASC Topic No. 740 - <i>Income Taxes</i>. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basic and diluted net loss per common share</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic and diluted net loss per share calculations are presented in accordance with FASB ASC Topic No. 260 &#8211; <i>Earnings per Share </i>and are calculated on the basis of the weighted average number of common shares outstanding during the period. Diluted per share calculations includes the dilutive effect of common stock equivalents in years with net income. <font style="color: rgb(34, 34, 34)">As the Company is in a loss position, any calculation of the dilutive effects of the Company&#8217;s convertible securities would reduce the loss per share amount, and, as such, the Company will not perform the calculation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Shipping and Handling Costs</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for shipping and handling fees in accordance with paragraph 605-45-45-19 of the FASB Accounting Standards Codification. While amounts charged to customers for shipping products are included in revenues, the related costs are classified in cost of revenue as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shipping and handling costs were $0 and $0 for the six months ended June 30, 2020 and 2019, respectively</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recently issued accounting pronouncements</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;In March 2020, the FASB issued ASU No. 2020-04, &#8220;<i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>.&#8221; ASU 2020-04 provides optional expedients and exceptions to account for contracts, hedging relationships and other transactions that reference LIBOR or another reference rate if certain criteria are met. The amendments of ASU No. 2020-04 are effective immediately, as of March 12, 2020, and may be applied prospectively to contract modifications made and hedging relationships entered into on or before December 31, 2022. The Company is evaluating the impact that the amendments of this standard would have on the Company&#8217;s consolidated financial statements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12, <i>Income Taxes(Topic 740): &#8220;Simplifying the Accounting for Income Taxes&#8221;</i>, which is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending existing guidance to improve consistent application. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. Certain amendments within this ASU are required to be applied on a retrospective basis, certain other amendments are required to be applied on a modified retrospective basis and all other amendments on a prospective basis. The Company is currently evaluating the impact the adoption of this standard will have on the consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (&#8220;ASU&#8221;) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s accrued expenses consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table align="center" cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center; text-indent: -8.65pt; padding-bottom: 1pt; padding-left: 8.65pt; white-space: nowrap">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap">June 30, 2020</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap">December 31, 2019</td> <td style="border-bottom: black 1pt solid">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 66%; text-align: left; text-indent: -8.65pt; padding-bottom: 1pt; padding-left: 8.65pt">Accrued officer salaries (see below)</td> <td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">5,105,900</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td> <td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">4,872,900</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; text-indent: -8.65pt; padding-bottom: 1pt; padding-left: 8.65pt">Accrued interest</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">196,187</td> <td style="text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">192,895</td> <td style="text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-indent: -8.65pt; padding-bottom: 1pt; padding-left: 8.65pt">Other</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,130,716</td> <td style="text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,026,569</td> <td style="text-align: left; padding-bottom: 1pt; white-space: nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -8.65pt; padding-bottom: 2.5pt; padding-left: 8.65pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">6,432,803</td> <td style="border-bottom: black 2.5pt double; text-align: left; white-space: nowrap">&#160;</td> <td style="border-bottom: black 2.5pt double">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">6,092,781</td> <td style="border-bottom: black 2.5pt double; text-align: left; white-space: nowrap">&#160;</td></tr></table> EX-101.CAL 8 gnth-20200630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 gnth-20200630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 gnth-20200630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Related Party [Axis] Antonio Milici [Member] Tannya Irizarry [Member] GTI Corporate Transfer Agents, LLC [Member] Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Shares To be Issued Preferred Stock Property, Plant and Equipment, Type [Axis] Office and Laboratory Equipment Range [Axis] Minimum [Member] Maximum [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Shell Company Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Entity File Number Entity Interactive Data Current Entity Incorporation, State or Country Code Document Annual Report Document Quarterly Report Statement [Table] Statement [Line Items] ASSETS Current assets Cash Prepaid expenses Total current assets Property and equipment Automobile & Trucks Less: Accumulated depreciation Total property and equipment, net Other assets - Deposit TOTAL ASSETS LIABILITIES & STOCKHOLDERS' DEFICIT LIABILITIES Current liabilities Accounts payable Accrued expenses Notes payable Convertible notes payable, net of discount Loan from shareholder Current liabilities Total liabilities Commitments and Contingencies Stockholders' deficit: Series A preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively; Series B preferred stock, par value $0.001 per share, 30,000,000 shares authorized, 26,038,572 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively Common stock, par value $0.001 per share, 300,000,000 shares authorized, 35,902,602 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively Common stock to be issued Additional paid-in capital Accumulated deficit Total stockholders' deficit of Genethera, Inc. TOTAL LIABILITIES & STOCKHOLDERS' DEFICIT Preferred Stock, Par Value Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Income Statement [Abstract] Expenses General and administrative expenses Payroll expenses Research and Development Depreciation Total operating expenses Loss from operations Other expenses Interest expense Total other expense Other Income Total other Income Net loss before income taxes Provision for income taxes Net loss Loss per common share - Basic and diluted Weighted average common shares outstanding -Basic and diluted Beginning Balance Beginning Balance, Shares Shares issued adjustment Shares issued adjustment (in shares) Net Loss Ending Balance Ending Balance,Shares Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Depreciation and amortization Shares issued for services Changes in operating assets and liabilities: Prepaid Expenses Deposits Accounts receivable - related parties Accounts payable and accrued expenses - related parties Accounts payable and accrued expenses Net cash used in operating activities Cash flows from investing activities Purchase of Fixed Asset Net cash used in investing activities Cash flows from financing activities Proceeds from convertible notes Net cash provided by financing activities Net decrease in cash Cash at the beginning of the year Cash at the end of the year Accounting Policies [Abstract] Organization and nature of operations and summary of significant accounting policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Property, Plant and Equipment [Abstract] Property and Equipment Related Party Transactions [Abstract] Related party transactions Payables and Accruals [Abstract] Accrued expenses Debt Disclosure [Abstract] Convertible notes payable Shareholders Equity Shareholders' equity Commitments and Contingencies Disclosure [Abstract] Commitments Subsequent Events [Abstract] Subsequent events Organization And Nature Of Operations And Summary Of Significant Accounting Policies Organization and nature of operations Basis of Presentation - Unaudited Financial Information Use of estimates Principles of consolidation Cash and cash equivalents Fair value of financial instruments Property and equipment, net Fair Value Instruments Reclassifications Impairment of long-lived assets Revenue recognition Leases Stock-Based Compensation Research and development costs Income taxes Basic and diluted net loss per common share Shipping and Handling Costs Recently issued accounting pronouncements Accrued Expenses Schedule of Accrued Expenses Statistical Measurement [Axis] Useful Life of Assets Going Concern Accumulated Deficit Working Capital Property and Equipment Loan Payable and Accrued Interest Transfer Agent Fees Security Deposit Accrued Expenses Accrued officer salaries Accrued interest Other Accrued expenses Shares to be issued Automobile and Trucks Common stock to be issued GTI Research, Inc. [Member] Office and Laboratory Equipment [Member] Shares to be Issued Shares to be Issued [Member] Working Capital Shares issued Adjustment (in shares) Assets, Current Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Other Expenses Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Shares, Outstanding Payments to Acquire Productive Assets Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] EX-101.PRE 11 gnth-20200630_pre.xml XBRL PRESENTATION FILE EX-101.SCH 12 gnth-20200630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and nature of operations and summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Accrued expenses link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Convertible notes payable link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Shareholders' equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Organization and nature of operations and summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Accrued expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization and nature of operations and summary of significant accounting policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Related party transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Shareholders' equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink XML 13 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2020
Aug. 14, 2020
Document And Entity Information    
Entity Registrant Name Genethera Inc  
Entity Central Index Key 0001017110  
Document Type 10-Q  
Document Period End Date Jun. 30, 2020  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Non-accelerated Filer  
Entity Common Stock, Shares Outstanding   35,902,602
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2020  
Entity Shell Company false  
Entity Emerging Growth Company false  
Entity Small Business true  
Entity File Number 000-27237  
Entity Interactive Data Current Yes  
Entity Incorporation, State or Country Code NV  
Document Quarterly Report true  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Current assets    
Cash $ 5,309
Prepaid expenses 922
Total current assets 922 5,309
Property and equipment    
Automobile & Trucks 26,400 26,400
Less: Accumulated depreciation (13,200) (10,560)
Total property and equipment, net 13,200 15,840
Other assets - Deposit
TOTAL ASSETS 14,122 21,149
Current liabilities    
Accounts payable 28,748 27,705
Accrued expenses 6,432,802 6,092,364
Notes payable 25,800 25,800
Convertible notes payable, net of discount 54,500 54,500
Loan from shareholder 735,330 741,778
Current liabilities 7,277,180 6,942,147
Total liabilities 7,277,180 6,942,147
Commitments and Contingencies
Stockholders' deficit:    
Common stock, par value $0.001 per share, 300,000,000 shares authorized, 35,902,602 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively 35,904 35,904
Common stock to be issued 53,572 53,572
Additional paid-in capital 23,448,986 23,448,986
Accumulated deficit (30,824,559) (30,485,499)
Total stockholders' deficit of Genethera, Inc. (7,260,058) (6,920,998)
TOTAL LIABILITIES & STOCKHOLDERS' DEFICIT 14,122 21,149
Series A Preferred Stock [Member]    
Stockholders' deficit:    
Series A preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively; Series B preferred stock, par value $0.001 per share, 30,000,000 shares authorized, 26,038,572 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively
Series B Preferred Stock [Member]    
Stockholders' deficit:    
Series A preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively; Series B preferred stock, par value $0.001 per share, 30,000,000 shares authorized, 26,038,572 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively $ 26,039 $ 26,039
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2020
Dec. 31, 2019
Common Stock, Par Value $ 0.001 $ 0.001
Common Stock, Shares Authorized 300,000,000 300,000,000
Common Stock, Shares Issued 35,902,602 35,902,602
Common Stock, Shares Outstanding 35,902,602 35,902,602
Series A Preferred Stock [Member]    
Preferred Stock, Par Value $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 20,000,000 20,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Series B Preferred Stock [Member]    
Preferred Stock, Par Value $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 30,000,000 30,000,000
Preferred Stock, Shares Issued 26,038,572 26,038,572
Preferred Stock, Shares Outstanding 26,038,572 26,038,572
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Expenses        
General and administrative expenses $ 76,241 $ 19,676 $ 100,128 $ 60,085
Payroll expenses 116,500 116,500 233,000 233,000
Research and Development
Depreciation 1,320 1,320 2,640 2,640
Total operating expenses 194,061 137,496 335,768 295,725
Loss from operations (194,061) (137,496) (335,768) (295,725)
Other expenses        
Interest expense (1,646) (9,512) (3,292) (19,024)
Total other expense (1,646) (9,512) (3,292) (19,024)
Other Income        
Total other Income
Net loss before income taxes (195,707) (147,008) (339,060) (314,749)
Provision for income taxes
Net loss $ (195,707) $ (147,008) $ (339,060) $ (314,749)
Loss per common share - Basic and diluted $ (0.01) $ (0.00) $ (0.01) $ (0.01)
Weighted average common shares outstanding -Basic and diluted 35,902,602 35,902,602 35,902,602 35,902,602
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Stockholders' (Deficit) (Unaudited) - USD ($)
Preferred Stock
Series A Preferred Stock [Member]
Preferred Stock
Series B Preferred Stock [Member]
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Shares To be Issued
Total
Beginning Balance at Dec. 31, 2018 $ 12 $ 26,039 $ 35,904 $ 22,568,815 $ (29,967,850) $ 53,572 $ (7,283,507)
Beginning Balance, Shares at Dec. 31, 2018 10,350 26,038,572 35,902,602        
Net Loss (314,749) (314,749)
Ending Balance at Jun. 30, 2019 $ 12 $ 26,039 $ 35,904 22,568,815 (30,282,599) 53,572 (7,598,256)
Ending Balance,Shares at Jun. 30, 2019 10,350 26,038,572 35,902,602        
Beginning Balance at Mar. 31, 2019 $ 12 $ 26,039 $ 35,904 22,568,815 (30,135,591) 53,572 (7,451,248)
Beginning Balance, Shares at Mar. 31, 2019 10,350 26,038,572 35,902,602        
Net Loss         (147,008) (147,008)
Ending Balance at Jun. 30, 2019 $ 12 $ 26,039 $ 35,904 22,568,815 (30,282,599) 53,572 (7,598,256)
Ending Balance,Shares at Jun. 30, 2019 10,350 26,038,572 35,902,602        
Beginning Balance at Dec. 31, 2019 $ 26,039 $ 35,904 23,448,986 (30,485,499) 53,572 (6,920,998)
Beginning Balance, Shares at Dec. 31, 2019 26,038,572 35,902,602        
Net Loss (339,060) (339,060)
Ending Balance at Jun. 30, 2020 $ 26,039 $ 36,504 23,448,986 (30,824,559) 53,572 (7,260,058)
Ending Balance,Shares at Jun. 30, 2020 26,038,572 35,902,602        
Beginning Balance at Mar. 31, 2020   $ 26,039 $ 35,904 23,448,986 (30,628,852) 53,572 (7,064,351)
Beginning Balance, Shares at Mar. 31, 2020   26,038,572 35,902,602        
Net Loss     (195,707) (195,707)
Ending Balance at Jun. 30, 2020 $ 26,039 $ 36,504 $ 23,448,986 $ (30,824,559) $ 53,572 $ (7,260,058)
Ending Balance,Shares at Jun. 30, 2020 26,038,572 35,902,602        
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Cash flows from operating activities    
Net loss $ (339,060) $ (314,749)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation
Depreciation and amortization 2,640 2,640
Shares issued for services
Changes in operating assets and liabilities:    
Prepaid Expenses (922) (852)
Deposits (3,000) 12,000
Accounts receivable - related parties
Accounts payable and accrued expenses - related parties (6,448)
Accounts payable and accrued expenses 341,481 295,921
Net cash used in operating activities (5,309) (5,040)
Cash flows from investing activities    
Purchase of Fixed Asset
Net cash used in investing activities
Cash flows from financing activities    
Proceeds from convertible notes
Net cash provided by financing activities
Net decrease in cash (5,309) (5,040)
Cash at the beginning of the year 5,309 5,040
Cash at the end of the year
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and nature of operations and summary of significant accounting policies
6 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Organization and nature of operations and summary of significant accounting policies

Note 1 – Organization and nature of operations and summary of significant accounting policies

 

Organization and nature of operations

 

The consolidated financial statements include GeneThera, Inc. and its wholly owned subsidiary GeneThera, Inc. (Colorado) (collectively, the “Company”). The Company had a long-standing research collaboration with GTI Research.

 

The Company is a biotechnology company that develops molecular assays and therapeutics for the detection and treatment for COVID-19 and other zoonotic diseases.

 

Basis of Presentation – Unaudited Financial Information

 

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2019 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC.

 

Use of estimates

 

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation.

 

Principles of consolidation

 

The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany accounts are eliminated upon consolidation.

 

Cash and cash equivalents

 

Cash equivalents are highly liquid investments with an original maturity of three months or less.

 

Fair Value of Financial Instruments

 

For purpose of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. The carrying amount of the Company’s short-term financial instruments approximates fair value due to the relatively short period to maturity for these instruments.

 

Property and equipment, net

 

Property and equipment consist primarily of office and laboratory equipment, leasehold improvements, vehicle, and is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives ranging from five to seven years. Leasehold improvements are amortized over the shorter of their economic lives or lease terms.

 

Fair Value of Financial Instruments

 

The Company follows ASC 820-10 of the FASB Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial instruments. ASC 820-10 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820-10 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by ASC 820-10 are described below:

 

Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
   
Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
   
Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data.
   

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

 

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.

 

Transactions involving related parties typically cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist.

 

Reclassifications

 

Certain prior period amounts have been reclassified to conform to current period presentation.

 

Impairment of Long-Lived Assets

 

The Company reviews the recoverability of its long-lived assets to determine whether events or changes in circumstances occurred that indicate the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the asset from the expected future cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying value. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.

 

Revenue recognition

 

There were no revenues during the six months ended June 30, 2020 and 2019, respectively.

 

The Company follows the FASB Accounting Standards Codification ASC 606 – Revenues from Contracts with Customers for revenue recognition. The Company considers revenue realized or realizable and earned when all the following criteria are met:

 

  1) Identification of the contract with a customer;

 

  2) Identification of the performance obligations in the contract;

 

  3) Determination of the transaction price;

 

  4) Allocation of the transaction price to the performance obligations in the contract; and

 

  5) Recognition of revenue when or as a performance obligation is satisfied. Revenue is recognized when each performance obligation is satisfied by the entity. An estimate of the variable consideration or performance obligations that an entity ultimately expects to be entitled to is included in the transaction price, and revenue is recognized upon satisfaction of the related performance obligation(s). An implicit or explicit significant financing component is taken into consideration. IP licenses must be analyzed. Each contract with customers is analyzed for multiple elements if any element must stand alone.

 

Leases

 

The lease agreement was terminated in April 2019. No right of use asset and liability were recorded for this lease.

 

On January 1, 2019, the Company adopted ASC 842 using the modified retrospective approach and will recognize a right of use (“ROU”) asset and liability in the consolidated balance sheet when and if the Company enters into a qualifying lease agreement.

 

At contract inception, the Company determines whether an arrangement is or contains a lease and whether the lease should be classified as an operating or a financing lease. A contract is or contains a lease if the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Control is determined based on the right to obtain all of the economic benefits from use of the identified asset and the right to direct the use of the identified asset. ROU assets for operating leases represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments.

 

Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement, as well as any variable rate payments that depend on an index, initially measured using the index at the lease commencement date. Non-lease components are accounted for separately from the fixed lease component for all leases. Most of the Company’s leases do not provide an implicit rate that can readily be determined. Therefore, the applied discount rate is based on the Company’s incremental borrowing rate, which is determined using its credit rating and other information available as of the commencement date and is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Lease terms may include options to renew, which the Company factors into the determination of the lease term when it is reasonably certain that the Company will exercise that option. The ROU asset is measured at the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.

 

Operating lease expense is recognized on a straight-line basis over the lease term and is included in “Cost of sales” and “Selling, general and administrative” line items in the Company’s consolidated statements of comprehensive income. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases is recognized on a straight-line basis over the lease term.

 

The Company monitors for events or changes in circumstances that require a reassessment of its leases. When a reassessment results in the premeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the ROU asset unless doing so would reduce the ROU asset to an amount less than zero, in which case the remaining adjustment would be recorded in the consolidated statements of comprehensive income.

 

Stock-Based Compensation

 

Stock-based compensation is accounted for under FASB ASC Topic No. 718 – Compensation – Stock Compensation. The guidance requires recognition in the financial statements of the cost of employee services received in exchange for an award of equity instruments over the period the employee is required to perform the services in exchange for the award (presumptively the vesting period). The guidance also requires measurement of the cost of employee services received in exchange for an award based on the grant-date fair value of the award. The Company accounts for non-employee share-based awards in accordance with guidance related to equity instruments that are issued to other than employees for acquisition, or in conjunction with selling, goods or services.

 

Research and development costs

 

R&D cost are currently expensed as incurred and primarily include cost associated with R&D arrangements with external parties in connection with the Company’s robotic technology project.

 

Income taxes

 

Income taxes are accounted for in accordance with the provisions of FASB ASC Topic No. 740 - Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized.

 

Basic and diluted net loss per common share

 

Basic and diluted net loss per share calculations are presented in accordance with FASB ASC Topic No. 260 – Earnings per Share and are calculated on the basis of the weighted average number of common shares outstanding during the period. Diluted per share calculations includes the dilutive effect of common stock equivalents in years with net income. As the Company is in a loss position, any calculation of the dilutive effects of the Company’s convertible securities would reduce the loss per share amount, and, as such, the Company will not perform the calculation.

 

Shipping and Handling Costs

 

The Company accounts for shipping and handling fees in accordance with paragraph 605-45-45-19 of the FASB Accounting Standards Codification. While amounts charged to customers for shipping products are included in revenues, the related costs are classified in cost of revenue as incurred.

 

Shipping and handling costs were $0 and $0 for the six months ended June 30, 2020 and 2019, respectively

 

Recently issued accounting pronouncements

 

 In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 provides optional expedients and exceptions to account for contracts, hedging relationships and other transactions that reference LIBOR or another reference rate if certain criteria are met. The amendments of ASU No. 2020-04 are effective immediately, as of March 12, 2020, and may be applied prospectively to contract modifications made and hedging relationships entered into on or before December 31, 2022. The Company is evaluating the impact that the amendments of this standard would have on the Company’s consolidated financial statements

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes(Topic 740): “Simplifying the Accounting for Income Taxes”, which is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending existing guidance to improve consistent application. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. Certain amendments within this ASU are required to be applied on a retrospective basis, certain other amendments are required to be applied on a modified retrospective basis and all other amendments on a prospective basis. The Company is currently evaluating the impact the adoption of this standard will have on the consolidated financial statements.

 

Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company.

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Going Concern
6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

Note 2- Going Concern

 

As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $30,824,559 and negative working capital of $7,276,258 as of June 30, 2020. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

 

Presently, the Company is considering ways to apply its molecular robotic technology to address the COVID-19 pandemic. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment
6 Months Ended
Jun. 30, 2020
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 3 – Property and Equipment

 

As of June 30, 2020, the Company had a vehicle with a net book value of $13,200.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Related party transactions
6 Months Ended
Jun. 30, 2020
Related Party Transactions [Abstract]  
Related party transactions

Note 4 – Related party transactions

 

The Company has an outstanding loan payable and accrued interest to Antonio Milici, its CEO and stockholder amounting to $679,783 as of June 30, 2020 and December 31, 2019, respectively. This outstanding loan to the Company is unsecured and bears interest at 2.41%. The Company has an outstanding loan and accrued interest payable to Tannya Irizarry, its interim CFO interim and stockholder, amounting to $55,547 and $61,995 as of June 30, 2020 and December 31, 2019, respectively. This outstanding loan to the Company is unsecured and bears interest at 8%.

 

Tannya Irizarry owns 50% of GTI Corporate Transfer Agents, LLC, and the Company’s transfer agency. During the six months ended June 30, 2020 and 2019, the Company made payments to GTI Corporate Transfer Agents, LLC in the amounts of $22,946 and $4,500, respectively.

 

The Company will no longer rely on GTI Research, Inc. (“GTIR”), the Company’s previous scientific robotic technology collaborator, for conducting research and development activities on the robotic technology development project. The lease agreement with GTI Research, Inc. was terminated on April 29, 2019. We have other collaborators which will be announced at a later time.

 

The Company utilizes Elia Holdings, LLC for construction and other maintenance services to maintain the Company’s office and lab space. Elia Holdings, LLC is controlled by Rene Irizarry. Costs incurred related to such services were $11,225 and $0 during the six-month periods ended June 30, 2020 and 2019, respectively.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued expenses
6 Months Ended
Jun. 30, 2020
Payables and Accruals [Abstract]  
Accrued expenses

Note 5 – Accrued expenses

 

The Company’s accrued expenses consisted of the following:

 

    June 30, 2020     December 31, 2019  
Accrued officer salaries (see below)   $ 5,105,900     $ 4,872,900  
Accrued interest     196,187       192,895  
Other     1,130,716       1,026,569  
    $ 6,432,803     $ 6,092,781  
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible notes payable
6 Months Ended
Jun. 30, 2020
Debt Disclosure [Abstract]  
Convertible notes payable

Note 6 – Convertible notes payable

 

The Company’s issued convertible notes are due on demand, bearing interest at an annual rate of 8%. The notes are convertible into shares of Company common stock at a conversion price of $0.01 to $0.05 per share. As of June 30, 2020 and December 31, 2019, the total outstanding principal and interest is $54,500.

 

As of December 31, 2019, an analysis of the principal amount of convertible notes payable that have elected conversion into common stock amounted to $366,000. The Company’s transfer agent has been constrained in its efforts to issue the common stock for these convertible notes due to the noncompliance of the Company’s filing requirements. The Company has ceased accruing interest on these convertible notes but continues to accrue interest on the remaining convertible notes of $54,500. The convertible notes that have elected conversion without the stock being issued have been included in ‘Accrued liabilities’ on the Balance Sheet.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' equity
6 Months Ended
Jun. 30, 2020
Shareholders Equity  
Shareholders' equity

Note 7 - Shareholders’ equity

 

Preferred Stock

 

The Company has authorized 20,000,000 shares of Series A Preferred Stock, $.001 par value, and 30,000,000 shares of Series B Preferred Stock, $.001 par value.

 

As of June 30, 2020, and December 31, 2019, the Company had 0 shares Series A Preferred Stock issued and outstanding, respectively.

 

As of June 30, 2020, and December 31, 2019, the Company had 26,038,572 shares of Series B Preferred Stock issued and outstanding, respectively.

 

Common stock

 

The Company has authorized 300,000,000 shares of its common stock, $.001 par value. The Company had issued and outstanding 35,902,602 shares as of June 30, 2020 and December 31, 2019, respectively.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments
6 Months Ended
Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments

Note 8 – Commitments

 

Employment Agreements

 

In 2017, the Company entered into five-year employment agreements with its chief executive and scientific officer and its chief administrative and financial officer. The agreements provide for compensation of $21,500 and $17,333 per month, respectively, and expires on January 31, 2022.

 

The agreements also provide for an aggregate bonus of $135,000 to be paid in Series B Preferred stock in March of each year of the agreement. There are not enough authorized shares to continue issuing the $135,000 worth of Series B Preferred stock, thus, beginning in 2019, the $135,000 was included as in the total payroll accrual.

 

Office Space Lease

 

The Company has a temporary office space at 4685 W 127th Pl, in Broomfield, CO as of June 30, 2020 until new space is completed after renovations. The lease term does not warrant the establishment of a right of use asset or liability. No asset or liability has been recorded on the balance sheet.

  

On April 3, 2020, GeneThera entered into a preliminary agreement with Green RV Storage LLC for the purchase of a 16,000 square foot building located in the planned Northwest 36 Biotechnology Center in Broomfield, Colorado. The new state of the art facility will be the Company administrative and R&D facility. The development is scheduled to be completed in fall of 2021.

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent events
6 Months Ended
Jun. 30, 2020
Subsequent Events [Abstract]  
Subsequent events

Note 9 – Subsequent events

 

The impact of COVID-19 on the Company is unknown at this time. The financial consequences of this situation cause uncertainty as to the future and its effects on the economy and the Company.

 

Presently, the Company is considering ways to apply its molecular robotic technology to address the COVID-19 pandemic

 

As of June 30, 2020, no additional conversions of convertible notes have occurred, and no new convertible notes have been issued.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and nature of operations and summary of significant accounting policies (Policies)
6 Months Ended
Jun. 30, 2020
Organization And Nature Of Operations And Summary Of Significant Accounting Policies  
Organization and nature of operations

Organization and nature of operations

 

The consolidated financial statements include GeneThera, Inc. and its wholly owned subsidiary GeneThera, Inc. (Colorado) (collectively, the “Company”). The Company had a long-standing research collaboration with GTI Research.

 

The Company is a biotechnology company that develops molecular assays and therapeutics for the detection and treatment for COVID-19 and other zoonotic diseases.

Basis of Presentation - Unaudited Financial Information

Basis of Presentation – Unaudited Financial Information

 

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2019 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC.

Use of estimates

Use of estimates

 

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation.

Principles of consolidation

Principles of consolidation

 

The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany accounts are eliminated upon consolidation.

Cash and cash equivalents

Cash and cash equivalents

 

Cash equivalents are highly liquid investments with an original maturity of three months or less.

Fair value of financial instruments

Fair Value of Financial Instruments

 

For purpose of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. The carrying amount of the Company’s short-term financial instruments approximates fair value due to the relatively short period to maturity for these instruments.

Property and equipment, net

Property and equipment, net

 

Property and equipment consist primarily of office and laboratory equipment, leasehold improvements, vehicle, and is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives ranging from five to seven years. Leasehold improvements are amortized over the shorter of their economic lives or lease terms.

Fair Value Instruments

Fair Value of Financial Instruments

 

The Company follows ASC 820-10 of the FASB Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial instruments. ASC 820-10 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820-10 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by ASC 820-10 are described below:

 

Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
   
Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
   
Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data.
   

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

 

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.

 

Transactions involving related parties typically cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist.

Reclassifications

Reclassifications

 

Certain prior period amounts have been reclassified to conform to current period presentation.

Impairment of long-lived assets

Impairment of Long-Lived Assets

 

The Company reviews the recoverability of its long-lived assets to determine whether events or changes in circumstances occurred that indicate the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the asset from the expected future cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying value. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.

Revenue recognition

Revenue recognition

 

There were no revenues during the six months ended June 30, 2020 and 2019, respectively.

 

The Company follows the FASB Accounting Standards Codification ASC 606 – Revenues from Contracts with Customers for revenue recognition. The Company considers revenue realized or realizable and earned when all the following criteria are met:

 

  1) Identification of the contract with a customer;

 

  2) Identification of the performance obligations in the contract;

 

  3) Determination of the transaction price;

 

  4) Allocation of the transaction price to the performance obligations in the contract; and

 

  5) Recognition of revenue when or as a performance obligation is satisfied. Revenue is recognized when each performance obligation is satisfied by the entity. An estimate of the variable consideration or performance obligations that an entity ultimately expects to be entitled to is included in the transaction price, and revenue is recognized upon satisfaction of the related performance obligation(s). An implicit or explicit significant financing component is taken into consideration. IP licenses must be analyzed. Each contract with customers is analyzed for multiple elements if any element must stand alone.
Leases

Leases

 

The lease agreement was terminated in April 2019. No right of use asset and liability were recorded for this lease.

 

On January 1, 2019, the Company adopted ASC 842 using the modified retrospective approach and will recognize a right of use (“ROU”) asset and liability in the consolidated balance sheet when and if the Company enters into a qualifying lease agreement.

 

At contract inception, the Company determines whether an arrangement is or contains a lease and whether the lease should be classified as an operating or a financing lease. A contract is or contains a lease if the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Control is determined based on the right to obtain all of the economic benefits from use of the identified asset and the right to direct the use of the identified asset. ROU assets for operating leases represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments.

 

Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement, as well as any variable rate payments that depend on an index, initially measured using the index at the lease commencement date. Non-lease components are accounted for separately from the fixed lease component for all leases. Most of the Company’s leases do not provide an implicit rate that can readily be determined. Therefore, the applied discount rate is based on the Company’s incremental borrowing rate, which is determined using its credit rating and other information available as of the commencement date and is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Lease terms may include options to renew, which the Company factors into the determination of the lease term when it is reasonably certain that the Company will exercise that option. The ROU asset is measured at the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.

 

Operating lease expense is recognized on a straight-line basis over the lease term and is included in “Cost of sales” and “Selling, general and administrative” line items in the Company’s consolidated statements of comprehensive income. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases is recognized on a straight-line basis over the lease term.

 

The Company monitors for events or changes in circumstances that require a reassessment of its leases. When a reassessment results in the premeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the ROU asset unless doing so would reduce the ROU asset to an amount less than zero, in which case the remaining adjustment would be recorded in the consolidated statements of comprehensive income.

Stock-Based Compensation

Stock-Based Compensation

 

Stock-based compensation is accounted for under FASB ASC Topic No. 718 – Compensation – Stock Compensation. The guidance requires recognition in the financial statements of the cost of employee services received in exchange for an award of equity instruments over the period the employee is required to perform the services in exchange for the award (presumptively the vesting period). The guidance also requires measurement of the cost of employee services received in exchange for an award based on the grant-date fair value of the award. The Company accounts for non-employee share-based awards in accordance with guidance related to equity instruments that are issued to other than employees for acquisition, or in conjunction with selling, goods or services.

Research and development costs

Research and development costs

 

R&D cost are currently expensed as incurred and primarily include cost associated with R&D arrangements with external parties in connection with the Company’s robotic technology project.

Income taxes

Income taxes

 

Income taxes are accounted for in accordance with the provisions of FASB ASC Topic No. 740 - Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized.

Basic and diluted net loss per common share

Basic and diluted net loss per common share

 

Basic and diluted net loss per share calculations are presented in accordance with FASB ASC Topic No. 260 – Earnings per Share and are calculated on the basis of the weighted average number of common shares outstanding during the period. Diluted per share calculations includes the dilutive effect of common stock equivalents in years with net income. As the Company is in a loss position, any calculation of the dilutive effects of the Company’s convertible securities would reduce the loss per share amount, and, as such, the Company will not perform the calculation.

Shipping and Handling Costs

Shipping and Handling Costs

 

The Company accounts for shipping and handling fees in accordance with paragraph 605-45-45-19 of the FASB Accounting Standards Codification. While amounts charged to customers for shipping products are included in revenues, the related costs are classified in cost of revenue as incurred.

 

Shipping and handling costs were $0 and $0 for the six months ended June 30, 2020 and 2019, respectively

Recently issued accounting pronouncements

Recently issued accounting pronouncements

 

 In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 provides optional expedients and exceptions to account for contracts, hedging relationships and other transactions that reference LIBOR or another reference rate if certain criteria are met. The amendments of ASU No. 2020-04 are effective immediately, as of March 12, 2020, and may be applied prospectively to contract modifications made and hedging relationships entered into on or before December 31, 2022. The Company is evaluating the impact that the amendments of this standard would have on the Company’s consolidated financial statements

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes(Topic 740): “Simplifying the Accounting for Income Taxes”, which is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending existing guidance to improve consistent application. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. Certain amendments within this ASU are required to be applied on a retrospective basis, certain other amendments are required to be applied on a modified retrospective basis and all other amendments on a prospective basis. The Company is currently evaluating the impact the adoption of this standard will have on the consolidated financial statements.

 

Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued expenses (Tables)
6 Months Ended
Jun. 30, 2020
Accrued Expenses  
Schedule of Accrued Expenses

The Company’s accrued expenses consisted of the following:

 

    June 30, 2020     December 31, 2019  
Accrued officer salaries (see below)   $ 5,105,900     $ 4,872,900  
Accrued interest     196,187       192,895  
Other     1,130,716       1,026,569  
    $ 6,432,803     $ 6,092,781  
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and nature of operations and summary of significant accounting policies (Details Narrative) - Office and Laboratory Equipment
6 Months Ended
Jun. 30, 2020
Minimum [Member]  
Useful Life of Assets 5 years
Maximum [Member]  
Useful Life of Assets 7 years
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Going Concern (Details Narrative) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Disclosure Going Concern Details Narrative Abstract    
Accumulated Deficit $ 30,824,559 $ 30,485,499
Working Capital   $ 7,276,258
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Details Narrative) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Property, Plant and Equipment [Abstract]    
Property and Equipment $ 13,200 $ 15,840
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Related party transactions (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Loan Payable and Accrued Interest $ 735,330   $ 735,330   $ 741,778
Research and Development  
Security Deposit    
Antonio Milici [Member]          
Loan Payable and Accrued Interest 679,783   679,783   679,783
Tannya Irizarry [Member]          
Loan Payable and Accrued Interest $ 55,547   55,547   $ 61,995
GTI Corporate Transfer Agents, LLC [Member]          
Transfer Agent Fees     $ 22,946 $ 600  
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued expenses (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Disclosure Accrued Expenses Details Abstract    
Accrued officer salaries $ 5,105,900 $ 4,872,900
Accrued interest 196,187 192,895
Other 1,130,716 1,026,569
Accrued expenses $ 6,432,802 $ 6,092,364
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' equity (Details Narrative) - $ / shares
Jun. 30, 2020
Dec. 31, 2019
Common Stock, Par Value $ 0.001 $ 0.001
Common Stock, Shares Authorized 300,000,000 300,000,000
Common Stock, Shares Issued 35,902,602 35,902,602
Common Stock, Shares Outstanding 35,902,602 35,902,602
Series A Preferred Stock [Member]    
Preferred Stock, Shares Authorized 20,000,000 20,000,000
Preferred Stock, Par Value $ 0.001 $ 0.001
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Series B Preferred Stock [Member]    
Preferred Stock, Shares Authorized 30,000,000 30,000,000
Preferred Stock, Par Value $ 0.001 $ 0.001
Preferred Stock, Shares Issued 26,038,572 26,038,572
Preferred Stock, Shares Outstanding 26,038,572 26,038,572
EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 37 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 38 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 76 192 1 false 13 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://genethera.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://genethera.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://genethera.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://genethera.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) (Unaudited) Sheet http://genethera.com/role/StatementsOfStockholdersDeficit Condensed Consolidated Statements of Stockholders' (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://genethera.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and nature of operations and summary of significant accounting policies Sheet http://genethera.com/role/OrganizationAndNatureOfOperationsAndSummaryOfSignificantAccountingPolicies Organization and nature of operations and summary of significant accounting policies Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://genethera.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment Sheet http://genethera.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Related party transactions Sheet http://genethera.com/role/RelatedPartyTransactions Related party transactions Notes 10 false false R11.htm 00000011 - Disclosure - Accrued expenses Sheet http://genethera.com/role/AccruedExpenses Accrued expenses Notes 11 false false R12.htm 00000012 - Disclosure - Convertible notes payable Notes http://genethera.com/role/ConvertibleNotesPayable Convertible notes payable Notes 12 false false R13.htm 00000013 - Disclosure - Shareholders' equity Sheet http://genethera.com/role/ShareholdersEquity Shareholders' equity Notes 13 false false R14.htm 00000014 - Disclosure - Commitments Sheet http://genethera.com/role/Commitments Commitments Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent events Sheet http://genethera.com/role/SubsequentEvents Subsequent events Notes 15 false false R16.htm 00000016 - Disclosure - Organization and nature of operations and summary of significant accounting policies (Policies) Sheet http://genethera.com/role/OrganizationAndNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies Organization and nature of operations and summary of significant accounting policies (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - Accrued expenses (Tables) Sheet http://genethera.com/role/AccruedExpensesTables Accrued expenses (Tables) Tables http://genethera.com/role/AccruedExpenses 17 false false R18.htm 00000018 - Disclosure - Organization and nature of operations and summary of significant accounting policies (Details Narrative) Sheet http://genethera.com/role/OrganizationAndNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and nature of operations and summary of significant accounting policies (Details Narrative) Details http://genethera.com/role/OrganizationAndNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies 18 false false R19.htm 00000019 - Disclosure - Going Concern (Details Narrative) Sheet http://genethera.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://genethera.com/role/GoingConcern 19 false false R20.htm 00000020 - Disclosure - Property and Equipment (Details Narrative) Sheet http://genethera.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://genethera.com/role/PropertyAndEquipment 20 false false R21.htm 00000021 - Disclosure - Related party transactions (Details Narrative) Sheet http://genethera.com/role/RelatedPartyTransactionsDetailsNarrative Related party transactions (Details Narrative) Details http://genethera.com/role/RelatedPartyTransactions 21 false false R22.htm 00000022 - Disclosure - Accrued expenses (Details) Sheet http://genethera.com/role/AccruedExpensesDetails Accrued expenses (Details) Details http://genethera.com/role/AccruedExpensesTables 22 false false R23.htm 00000023 - Disclosure - Shareholders' equity (Details Narrative) Sheet http://genethera.com/role/ShareholdersEquityDetailsNarrative Shareholders' equity (Details Narrative) Details http://genethera.com/role/ShareholdersEquity 23 false false All Reports Book All Reports gnth-20200630.xml gnth-20200630.xsd gnth-20200630_cal.xml gnth-20200630_def.xml gnth-20200630_lab.xml gnth-20200630_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 41 0001199835-20-000216-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001199835-20-000216-xbrl.zip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